Mycophenolate sodium treatment in patients with primary Sjögren syndrome: a pilot trial

Table 2 Clinical characteristics of patients

Patient	Age in years	Gender	Disease duration in years	Anti-SSA/Anti-SSB/RF	Extraglandular manifestations	Prednisolone (mg/day)	Adverse events
1^a	59	Female	13	+/+/+	Arthralgia	-	Vertigo, perspiration
2	46	Female	12	+/+/+	LP, RS	-	GI discomfort, common cold
3^a	50	Female	15	+/+/+	Arthralgia, RS, LP	-	GI discomfort
4	67	Female	17	+/+/+	Arthralgia, RS	2.5	None
5	60	Female	4	+/+/+	Arthralgia, LP, VA	-	GI discomfort^b
6^a	61	Female	5	+/+/+	Arthralgia, LP	-	Pneumonia
7	53	Female	13	+/-/+	LP, PNP	2.5	GI discomfort, herpes labialis
8	40	Female	2	+/-/-	Arthralgia, LP	-	None
9	35	Female	12	+/-/+	LP, RS	5	None
10	44	Female	9	+/+/+	Arthralgia, RS	-	Palpitation, perspiration^b
11	36	Female	2	+/+/-	Arthralgia	-	Common cold

^aPatients 1, 3, and 6 did not complete the study; ^bdose was reduced to 720 mg/day after week 12. GI, gastrointestinal; LP, leukopenia; PNP, polyneuropathy; RF, rheumatoid factor; RS, Raynaud syndrome; VA, vasculitis.

ISSN: 1478-6362